ArticleInternational journal of nanomedicine2017
Composite iron oxide-Prussian blue nanoparticles for magnetically guided T
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Biodegradable Prussian blue/manganese dioxide core-shell nanoparticles with open cages for imaging-guided chemo-photothermal combined therapy of cancer cells.RSC advances · 2026Article
- Synthesis of MnFeNanomaterials (Basel, Switzerland) · 2025Article
- A review of combined imaging and therapeutic applications based on MNMs.Frontiers in chemistry · 2025Review
- Iron Oxide Nanoparticles: Parameters for Optimized Photoconversion Efficiency in Synergistic Cancer Treatment.Journal of functional biomaterials · 2024Review
- Smart Biomimetic Nanozymes for Precise Molecular Imaging: Application and Challenges.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Polymeric magnetic nanoparticles: a multitargeting approach for brain tumour therapy and imaging.Drug delivery and translational research · 2022Review
- Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma.Frontiers in pharmacology · 2022Review
- An Engineered Prussian Blue Nanoparticles-based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH-MYCN Neuroblastoma Model.Advanced nanobiomed research · 2021Article
- Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy.Advanced healthcare materials · 2021Review
- CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma.Translational oncology · 2020Article
- Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Gadolinium-doped Au@prussian blue nanoparticles as MR/SERS bimodal agents for dendritic cell activating and tracking.Theranostics · 2020Article
- Review
- Polymer coated gold-ferric oxide superparamagnetic nanoparticles for theranostic applications.Journal of nanobiotechnology · 2018Article
- Iron Oxide Nanoparticles in Photothermal Therapy.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostic nanoparticles offer the potential for mixing and matching disparate diagnostic and therapeutic functionalities within a single nanoparticle for the personalized treatment of diseases. In this article, we present composite iron oxide-gadolinium-containing Prussian blue nanoparticles (Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.